This company listing is no longer active
0AAX Stock Overview
IGEA Pharma N.V. commercializes health-tech and med-tech products and devices in the Netherlands and rest of Europe. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
IGEA Pharma N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 0.009 |
| 52 Week High | CHF 0.21 |
| 52 Week Low | CHF 0.009 |
| Beta | -0.29 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -90.53% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0AAX | GB Medical Equipment | GB Market | |
|---|---|---|---|
| 7D | 0% | 2.3% | 0.3% |
| 1Y | n/a | -6.5% | 10.4% |
Return vs Industry: Insufficient data to determine how 0AAX performed against the UK Medical Equipment industry.
Return vs Market: Insufficient data to determine how 0AAX performed against the UK Market.
Price Volatility
| 0AAX volatility | |
|---|---|
| 0AAX Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 6.7% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.4% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0AAX has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 0AAX's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 1 | Pierpaolo Cerani | www.igeapharma.nl |
IGEA Pharma N.V. commercializes health-tech and med-tech products and devices in the United States and the Netherlands. It offers Alz1, an at-home lab test kit to measure non-bound copper in the blood; dietary supplement products to reduce blood heavy metals content under the Alz1 Tab brand; and COVID19 rapid test for the detection of IgM and IgG SARS-CoV-2 related antibodies. The company also provides dry aerosol generators for air and inanimate environmental surfaces sanitization, as well as air sterilization and purification devices.
IGEA Pharma N.V. Fundamentals Summary
| 0AAX fundamental statistics | |
|---|---|
| Market cap | CHF 1.69m |
| Earnings (TTM) | -CHF 714.08k |
| Revenue (TTM) | CHF 87.50k |
19.3x
P/S Ratio-2.4x
P/E RatioIs 0AAX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0AAX income statement (TTM) | |
|---|---|
| Revenue | €90.80k |
| Cost of Revenue | €63.90k |
| Gross Profit | €26.90k |
| Other Expenses | €767.90k |
| Earnings | -€741.00k |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0022 |
| Gross Margin | 29.63% |
| Net Profit Margin | -816.08% |
| Debt/Equity Ratio | 11.0% |
How did 0AAX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/07/24 16:47 |
| End of Day Share Price | 2023/04/26 00:00 |
| Earnings | 2022/06/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
IGEA Pharma N.V. is covered by 1 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Matthias Greiffenberger | GBC AG |